SK12282002A3 - Mezylát a polymorfy 4-amino-6,7-dimetoxy-2-(5-metansulfónamido- 1,2,3,4-tetrahydroizochinol-2-yl)-5-(2-pyridyl)chinazolínu - Google Patents

Mezylát a polymorfy 4-amino-6,7-dimetoxy-2-(5-metansulfónamido- 1,2,3,4-tetrahydroizochinol-2-yl)-5-(2-pyridyl)chinazolínu Download PDF

Info

Publication number
SK12282002A3
SK12282002A3 SK1228-2002A SK12282002A SK12282002A3 SK 12282002 A3 SK12282002 A3 SK 12282002A3 SK 12282002 A SK12282002 A SK 12282002A SK 12282002 A3 SK12282002 A3 SK 12282002A3
Authority
SK
Slovakia
Prior art keywords
dimethoxy
pyridyl
quinazoline
amino
methanesulfonamido
Prior art date
Application number
SK1228-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Patricia Ann Basford
Paul Blaise Hodgson
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005200A external-priority patent/GB0005200D0/en
Priority claimed from GB0015900A external-priority patent/GB0015900D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SK12282002A3 publication Critical patent/SK12282002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1228-2002A 2000-03-03 2001-02-23 Mezylát a polymorfy 4-amino-6,7-dimetoxy-2-(5-metansulfónamido- 1,2,3,4-tetrahydroizochinol-2-yl)-5-(2-pyridyl)chinazolínu SK12282002A3 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005200A GB0005200D0 (en) 2000-03-03 2000-03-03 New salt form
GB0015900A GB0015900D0 (en) 2000-06-28 2000-06-28 New salt form
PCT/IB2001/000244 WO2001064672A1 (en) 2000-03-03 2001-02-23 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs

Publications (1)

Publication Number Publication Date
SK12282002A3 true SK12282002A3 (sk) 2003-10-07

Family

ID=26243792

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1228-2002A SK12282002A3 (sk) 2000-03-03 2001-02-23 Mezylát a polymorfy 4-amino-6,7-dimetoxy-2-(5-metansulfónamido- 1,2,3,4-tetrahydroizochinol-2-yl)-5-(2-pyridyl)chinazolínu

Country Status (40)

Country Link
US (1) US6683085B2 (da)
EP (1) EP1268468B1 (da)
JP (1) JP3857919B2 (da)
KR (1) KR100496089B1 (da)
CN (1) CN1214029C (da)
AP (1) AP2002002611A0 (da)
AR (1) AR029482A1 (da)
AT (1) ATE253570T1 (da)
AU (1) AU779118B2 (da)
BG (1) BG106869A (da)
BR (1) BR0108910A (da)
CA (1) CA2398963C (da)
CR (1) CR6731A (da)
CZ (1) CZ20022858A3 (da)
DE (1) DE60101157T2 (da)
DK (1) DK1268468T3 (da)
EA (1) EA004748B1 (da)
EE (1) EE200200496A (da)
ES (1) ES2208565T3 (da)
GE (1) GEP20043364B (da)
HK (1) HK1053655A1 (da)
HN (1) HN2001000036A (da)
HR (1) HRP20020718A2 (da)
HU (1) HUP0300006A3 (da)
IL (1) IL150634A0 (da)
IS (1) IS6441A (da)
MA (1) MA26876A1 (da)
MX (1) MXPA02008665A (da)
NO (1) NO20024195L (da)
NZ (1) NZ519672A (da)
OA (1) OA12186A (da)
PE (1) PE20011225A1 (da)
PL (1) PL365070A1 (da)
PT (1) PT1268468E (da)
SI (1) SI1268468T1 (da)
SK (1) SK12282002A3 (da)
TN (1) TNSN01034A1 (da)
TR (1) TR200302130T4 (da)
UA (1) UA72311C2 (da)
WO (1) WO2001064672A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
DE10223913A1 (de) * 2002-05-29 2003-12-11 Bayer Cropscience Ag Verfahren zur Herstellung spezifischer Kristallmodifikationen polymorpher Substanzen
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914114A (en) 1984-05-28 1990-04-03 Merck Patent Gesellschaft Mit Breschrankter Haftung 3-[4-(4-phenyl-1,2,3,6-tetrahydro-1-pyridyl)butyl]-5-hydroxy-indole methanesulfonate having sedating and anti-parkinsonism properties
EP0281608B1 (de) * 1986-09-16 1990-07-11 MERCK PATENT GmbH Hydroxyindolderivat
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CZ20022858A3 (cs) 2003-09-17
WO2001064672A1 (en) 2001-09-07
MA26876A1 (fr) 2004-12-20
PE20011225A1 (es) 2001-12-08
EA004748B1 (ru) 2004-08-26
IS6441A (is) 2002-06-25
HK1053655A1 (en) 2003-10-31
HN2001000036A (es) 2001-07-09
HRP20020718A2 (en) 2004-02-29
HUP0300006A3 (en) 2006-01-30
US20020010188A1 (en) 2002-01-24
AP2002002611A0 (en) 2002-09-30
CN1214029C (zh) 2005-08-10
BR0108910A (pt) 2002-12-24
CR6731A (es) 2004-03-11
NO20024195D0 (no) 2002-09-03
CN1432010A (zh) 2003-07-23
AU779118B2 (en) 2005-01-06
DE60101157T2 (de) 2004-09-02
UA72311C2 (uk) 2005-02-15
EP1268468A1 (en) 2003-01-02
KR100496089B1 (ko) 2005-06-17
TNSN01034A1 (fr) 2005-11-10
SI1268468T1 (en) 2004-04-30
US6683085B2 (en) 2004-01-27
EP1268468B1 (en) 2003-11-05
ATE253570T1 (de) 2003-11-15
CA2398963C (en) 2006-10-24
PL365070A1 (en) 2004-12-27
ES2208565T3 (es) 2004-06-16
TR200302130T4 (tr) 2004-01-21
AU3588801A (en) 2001-09-12
DE60101157D1 (de) 2003-12-11
PT1268468E (pt) 2004-01-30
NZ519672A (en) 2004-06-25
EE200200496A (et) 2004-02-16
MXPA02008665A (es) 2003-02-24
CA2398963A1 (en) 2001-09-07
JP2003525289A (ja) 2003-08-26
GEP20043364B (en) 2004-03-10
JP3857919B2 (ja) 2006-12-13
AR029482A1 (es) 2003-07-02
EA200200826A1 (ru) 2003-02-27
NO20024195L (no) 2002-09-03
BG106869A (bg) 2002-12-29
IL150634A0 (en) 2003-02-12
OA12186A (en) 2006-05-09
HUP0300006A2 (en) 2003-05-28
DK1268468T3 (da) 2004-02-09
KR20020080463A (ko) 2002-10-23

Similar Documents

Publication Publication Date Title
US7423040B2 (en) Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
MX2008015646A (es) Nuevas sales y formas de sales cristalinas de un derivado de indolinona.
KR101212908B1 (ko) 무스카린 수용체 안타고니스트의 안정한 수화물
KR20140138941A (ko) 상피 성장 인자 수용체 키나제 억제제의 염
US20060030602A1 (en) (S)-amlodipine malate
SK12282002A3 (sk) Mezylát a polymorfy 4-amino-6,7-dimetoxy-2-(5-metansulfónamido- 1,2,3,4-tetrahydroizochinol-2-yl)-5-(2-pyridyl)chinazolínu
SK285774B6 (sk) Eletriptan hydrobromid monohydrát, spôsoby jeho prípravy a použitie, farmaceutická kompozícia s jeho obsahom a spôsob prípravy bezvodného eletriptan hydrobromidu
KR20020032627A (ko) 다형태 염
US20110200687A1 (en) Bifeprunox mesylate maintenance dose compositions and methods for using the same
US20020128296A1 (en) Aspartate derivative of amlodipine
TW201125861A (en) CDC7 inhibitor salts
JP2003128653A (ja) 結晶性物質
KR20080087803A (ko) 디히드로피리딘 유도체의 산부가염
WO1999020623A1 (en) Indole derivative useful as endothelin receptor antagonist
ZA200207016B (en) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs.
JPS61249970A (ja) 新規な置換２−（ｎ−アルキニル−ｎ−フエニルアミノ）イミダゾリン誘導体
AU2001100438A4 (en) Aspartate derivative of amlodipine
EP1541146B1 (en) Zolpidem hemitartrate solvate